Nektar Therapeutics Reports Second Quarter 2010 Financial Results
Jul 28, 2010
|
16.7 KB |
Nektar to Announce Financial Results for the Second Quarter of 2010 On Wednesday, July 28, 2010, After Close of U.S.-Based Financial Markets
Jul 21, 2010
|
6.7 KB |
NKTR-102 Demonstrates Superior Activity to Irinotecan in Nonclinical Studies Presented at ESMO 12th World Congress on Gastrointestinal Cancer
Jul 6, 2010
|
12.8 KB |
Nektar Announces Dosing of First Patients in Phase 1 Clinical Study of NKTR-102 in Combination With 5-Fluorouracil/Leucovorin
Jun 24, 2010
|
13.4 KB |
Nektar Therapeutics Announces Positive Initial Results from Phase 2 Study of NKTR-102 in Metastatic Breast Cancer
Jun 9, 2010
|
13.1 KB |
NKTR-102 Has High Response Rate and Sustained Clinical Benefit in 48 Percent of Women with Platinum-Resistant/Refractory Ovarian Cancer
Jun 6, 2010
|
22.3 KB |
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the Jefferies 2010 Global Life Sciences Healthcare Conference in New York
Jun 3, 2010
|
8.5 KB |
NKTR-102 Phase 2 Clinical Data Accepted for Oral Presentation at 2010 ASCO Annual Meeting
May 20, 2010
|
13.5 KB |
Nektar Therapeutics Reports First Quarter 2010 Financial Results
May 5, 2010
|
15.6 KB |
Nektar to Announce Financial Results for the First Quarter of 2010 on Wednesday, May 5, 2010, After Close of U.S.-Based Financial Markets
Apr 27, 2010
|
7.6 KB |
Nektar Announces Positive Phase 2 Clinical Data from First Stage of NKTR-102 Study in Women with Platinum-Resistant Ovarian Cancer
Mar 8, 2010
|
13.3 KB |
Nektar Therapeutics' President and CEO Howard W. Robin to Present at the 30th Annual Cowen and Company Healthcare Conference in Boston
Mar 2, 2010
|
8.4 KB |
Nektar Therapeutics Reports Year-End 2009 Financial Results
Mar 2, 2010
|
17.6 KB |
Nektar to Announce Year-End 2009 Financial Results on Tuesday, March 2, 2010, After Close of U.S.-Based Financial Markets
Feb 23, 2010
|
7.6 KB |
Nektar Therapeutics Appoints R. Scott Greer to Board of Directors
Feb 2, 2010
|
8.7 KB |
Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer
Jan 12, 2010
|
13.5 KB |
Nektar Therapeutics Names Stephen K. Doberstein, Ph.D. Senior Vice President and Chief Scientific Officer
Jan 6, 2010
|
9.1 KB |
Nektar Therapeutics' President and CEO, Howard W. Robin, to Present at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
Jan 6, 2010
|
6.2 KB |
Dennis Winger Joins Nektar Therapeutics' Board of Directors
Dec 14, 2009
|
7.1 KB |
Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
Nov 30, 2009
|
8.7 KB |
|
|
